SUMMARY: Iptacopan has been awarded the Innovation Passport for the treatment of C3 glomerulopathy (C3G)…
Monthly Archives
October 2021
-
-
ChemIntelligence
Union Health Minister expands Pneumococcal Conjugate Vaccine Under Universal Immunization Program.
by adminSUMMARY: Union Minister for Health and Family Welfare, Dr Mansukh Mandaviya launched the nationwide expansion…
-
Asciminib
FDA approves Novartis Scemblix® (Asciminib) for Certain Patients with Philadelphia Chromosome (Ph)–positive Chronic Myeloid Leukemia.
by adminKeypoints: The FDA granted accelerated approval to Asciminib for the treatment of patients with Philadelphia…
-
CabotegravirRilpivirine
European Commission Grants Decision for Vocabria (Cabotegravir) and Rekambys (Rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV
by adminSUMMARY: ViiV Healthcare announces the European Commission Decision for Vocabria (Cabotegravir) and Rekambys (Rilpivirine) injections…
-
The Department of Pharmaceuticals (DoP) has come out with a draft policy to catalyse…
-
ChemIntelligence
FDA, NIH, and 15 Private Organizations have partnered to Increase Effective Gene Therapies for Rare Diseases.
by adminSUMMARY: The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies…
-
Introduction The Medical Device industry is highly capital intensive with a long gestation period and…
-
ChemIntelligence
The Union Health Minister Dr. Mansukh Mandaviya launches the Sixth Edition of The National Formulary of India (NFI).
by adminSUMMARY: Union Health Minister Mansukh Mandaviya on Thursday launched the sixth edition of the National…
-
Pitolisant
Bioprojet’s Ozawade (Pitolisant) gets Approval for the Treatment of Excessive Daytime Sleepiness (EDS) associated with Obstructive Sleep Apnoea (OSA) in Adults.
by adminSUMMARY: EMA-approved medicine for excessive daytime sleepiness med Ozawade (Pitolisant) Pitolisant was developed after decades of…
-
Novartis
Novartis’s BLA has been accepted by US FDA & EMA for Kymriah (Tisagenlecleucel) to treat patients with relapsed or refractory follicular lymphoma.
by adminNovartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T…
Newer Posts